Champions Oncology (CSBR)
(Delayed Data from NSDQ)
$4.60 USD
-0.05 (-1.08%)
Updated Jun 7, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Champions Oncology, Inc. [CSBR]
Reports for Purchase
Showing records 21 - 38 ( 38 total )
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
FY4Q21 Recap - Investing for Sustainable Growth
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
FY4Q20 Recap - Messy Quarter, but Revenue Outlook Strong
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
FY2Q20 Recap - Solid Quarter Offset by Truncated Guidance
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
We launch coverage with a Buy rating and a $9.25/share price target.
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Company: Champions Oncology, Inc.
Industry: Medical - Drugs
Champions Oncology reported very positive quarterly earnings earlier this month.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R